Proteasome inhibition for antibody-mediated rejection
JJ Everly, RC Walsh, RR Alloway… - Current Opinion in …, 2009 - journals.lww.com
JJ Everly, RC Walsh, RR Alloway, ES Woodle
Current Opinion in Organ Transplantation, 2009•journals.lww.comProteasome inhibition induces a complex series of biochemical events that results in
pleiotropic effects on multiple cell populations, and plasma cells in particular. Initial clinical
results have provided evidence that bortezomib effectively treats antibody-mediated
rejection and acute cellular rejection and reduces or eliminates donor-specific anti-human
leukocyte antigen antibody. Carefully designed clinical trials are needed to accurately define
the role of proteasome inhibition in transplant recipients.
pleiotropic effects on multiple cell populations, and plasma cells in particular. Initial clinical
results have provided evidence that bortezomib effectively treats antibody-mediated
rejection and acute cellular rejection and reduces or eliminates donor-specific anti-human
leukocyte antigen antibody. Carefully designed clinical trials are needed to accurately define
the role of proteasome inhibition in transplant recipients.
Summary
Proteasome inhibition induces a complex series of biochemical events that results in pleiotropic effects on multiple cell populations, and plasma cells in particular. Initial clinical results have provided evidence that bortezomib effectively treats antibody-mediated rejection and acute cellular rejection and reduces or eliminates donor-specific anti-human leukocyte antigen antibody. Carefully designed clinical trials are needed to accurately define the role of proteasome inhibition in transplant recipients.
Lippincott Williams & Wilkins